Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Ironwood Pharmaceuticals Inc. | Apraglutide - (STARGAZE) | Acute Graft-Versus-Host Disease | Phase 2 | Ongoing | Subcutaneous | Immunosuppressant |
| Ironwood Pharmaceuticals Inc. | Apraglutide - (STARS Nutrition) | Short bowel syndrome - colon-in-continuity | Phase 2 | Data Released | Subcutaneous | Gastroenterology |
| Ironwood Pharmaceuticals Inc. | MD-7246 | Irritable Bowel Syndrome | Phase 2 | Trial Discontinued | Oral | Gastroenterology |
| Ironwood Pharmaceuticals Inc. | IW-9179 | Gastroparesis | Phase 2a | Trial Discontinued | Oral | Gastroenterology |
| iTeos Therapeutics Inc. | Belrestotug + dostarlimab - (GALAXIES Lung-301) | PD-L1 selected non-small cell lung cancer (NSCLC) | Phase 3 | Trial Discontinued | Intravenous | Oncology |
| iTeos Therapeutics Inc. | Belrestotug + dostarlimab + GSK562 - (GSK6097608) | Advanced solid tumors | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| iTeos Therapeutics Inc. | Belrestotug (EOS-448/GSK4428859A) - (TIG-006 mNSCLC, ENTRÉE) | 1L in advanced or metastatic Non-small cell lung cancer (NSCLC) | Phase 2 | Ongoing | Intravenous | Oncology |
| iTeos Therapeutics Inc. | Belrestotug (EOS-448/GSK4428859A) - (TIG-006 HNSCC) | PD-L1 positive advanced or metastatic head and neck squamous cell carcinoma (HNSCC) | Phase 2 | Ongoing | Intravenous | Oncology |
